Literature DB >> 14756670

The Delta>15 Kb deletion French Canadian founder mutation in familial hypercholesterolemia: rapid polymerase chain reaction-based diagnostic assay and prevalence in Quebec.

L R Simard1, J Viel, M Lambert, G Paradis, E Levy, E E Delvin, G A Mitchell.   

Abstract

Approximately one in 500 individuals in Western population has autosomal dominant familial hypercholesterolemia due to mutations in the low-density lipoprotein receptor (LDLR) gene. Screening for these mutations is hampered by their large number, except in founder populations. We identified the breakpoint of the >15 kb deletion involving the LDLR gene promoter and exon 1, responsible for more than 60% of French Canadian hypercholesterolemia cases, as well as the breakpoint of the 5 kb deletion of exons 2 and 3 that accounts for an additional 5% of cases. Both deletions appear to be because of homologous recombination by unequal crossing-over between the left arms of Alu repeats. Using RepeatMasker, we determined that 55% of the LDLR gene is composed of Alu elements; thus, it is not surprising that most LDLR rearrangements involve at least one Alu. Furthermore, we developed a rapid polymerase chain reaction-based assay for the French Canadian-1 (>15 kb) and French Canadian-5 (5 kb) hypercholesterolemia alleles. Screening a representative population sample of 943 French Canadian youths whose LDL cholesterol levels were above the 50th percentile allowed us to estimate the prevalence of the >15 kb allele as 0.11% (95% confidence interval, 0.03-0.38).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14756670     DOI: 10.1111/j.0009-9163.2004.00223.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  6 in total

1.  Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis.

Authors:  Carol Dobson-Stone; Antonio Velayos-Baeza; An Jansen; Frederick Andermann; François Dubeau; Francine Robert; Anne Summers; Anthony E Lang; Sylvain Chouinard; Adrian Danek; Eva Andermann; Anthony P Monaco
Journal:  Neurogenetics       Date:  2005-09-28       Impact factor: 2.660

2.  Gross deletions involving IGHM, BTK, or Artemis: a model for genomic lesions mediated by transposable elements.

Authors:  Menno C van Zelm; Corinne Geertsema; Nicole Nieuwenhuis; Dick de Ridder; Mary Ellen Conley; Claudine Schiff; Ilhan Tezcan; Ewa Bernatowska; Nico G Hartwig; Elisabeth A M Sanders; Jiri Litzman; Irina Kondratenko; Jacques J M van Dongen; Mirjam van der Burg
Journal:  Am J Hum Genet       Date:  2008-02       Impact factor: 11.025

3.  Genomic characterization of five deletions in the LDL receptor gene in Danish Familial Hypercholesterolemic subjects.

Authors:  Peter H Nissen; Dorte Damgaard; Anette Stenderup; Gitte G Nielsen; Mogens L Larsen; Ole Faergeman
Journal:  BMC Med Genet       Date:  2006-06-26       Impact factor: 2.103

4.  Validation of Genome-Wide Polygenic Risk Scores for Coronary Artery Disease in French Canadians.

Authors:  Florian Wünnemann; Ken Sin Lo; Alexandra Langford-Avelar; David Busseuil; Marie-Pierre Dubé; Jean-Claude Tardif; Guillaume Lettre
Journal:  Circ Genom Precis Med       Date:  2019-06-11

5.  Three patients with homozygous familial hypercholesterolemia: Genomic sequencing and kindred analysis.

Authors:  Karen H Y Wong; Michal Levy-Sakin; Walfred Ma; Nina Gonzaludo; Angel C Y Mak; Dedeepya Vaka; Annie Poon; Catherine Chu; Richard Lao; Melek Balamir; Zoe Grenville; Nicolas Wong; John P Kane; Pui-Yan Kwok; Mary J Malloy; Clive R Pullinger
Journal:  Mol Genet Genomic Med       Date:  2019-10-16       Impact factor: 2.183

6.  Saudi Familial Hypercholesterolemia Patients With Rare LDLR Stop Gain Variant Showed Variable Clinical Phenotype and Resistance to Multiple Drug Regimen.

Authors:  Zuhier Ahmed Awan; Omran M Rashidi; Bandar Ali Al-Shehri; Kaiser Jamil; Ramu Elango; Jumana Y Al-Aama; Robert A Hegele; Babajan Banaganapalli; Noor A Shaik
Journal:  Front Med (Lausanne)       Date:  2021-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.